In MASLD patients, alterations in the gut microbiota result in an overall increase in total BA levels, accompanied by a concurrent decrease in the proportion of BAs that act as FXR and TGR5 agonists. The gene discussed is GPBAR1; the disease is metabolic dysfunction-associated steatotic liver disease.